Safety and immunogenicity of live intranasal pertussis vaccine GamLVP in the experimental infant hamadryas baboon model
Introduction. The Gamaleya National Center of Epidemiology and Microbiology has developed a live intranasal pertussis vaccine, GamLVP, for protection against whooping cough. It is indicated for vaccination of infants and revaccination of adults of all age groups. Preclinical studies on suckling mice...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Central Research Institute for Epidemiology
2022-05-01
|
| Series: | Журнал микробиологии, эпидемиологии и иммунобиологии |
| Subjects: | |
| Online Access: | https://microbiol.elpub.ru/jour/article/view/1218 |
| _version_ | 1811285265977704448 |
|---|---|
| author | A. A. Djidaryan A. Z. Matua A. Yu. Medkova E. G. Semin L. N. Sinyashina I. N. Dyakov I. N. Chernyshova D. T. Kubrava A. A. Amichba I. G. Kondzariya Z. Ya. Mikvabiya G. I. Karataev |
| author_facet | A. A. Djidaryan A. Z. Matua A. Yu. Medkova E. G. Semin L. N. Sinyashina I. N. Dyakov I. N. Chernyshova D. T. Kubrava A. A. Amichba I. G. Kondzariya Z. Ya. Mikvabiya G. I. Karataev |
| author_sort | A. A. Djidaryan |
| collection | DOAJ |
| description | Introduction. The Gamaleya National Center of Epidemiology and Microbiology has developed a live intranasal pertussis vaccine, GamLVP, for protection against whooping cough. It is indicated for vaccination of infants and revaccination of adults of all age groups. Preclinical studies on suckling mice or rats and adult monkeys as well as clinical trials involving adult volunteers demonstrated safety and efficacy of the GamLVP vaccine. The expansion of the GamLVP vaccine to be used for vaccination of infants requires additional preclinical studies to assess its safety and immunogenicity in the most suitable experimental model of infant hamadryas baboons (Papio hamadryas).The aim of the study was to assess safety and immunogenicity of the GamLVP vaccine administered intranasally for a single dose, two-dose, and three-dose immunization of P. hamadryas infants.Materials and methods. The study was performed in three 1–2-month-old P. hamadryas infants kept, together with their mothers, in a separate cage. The results of the complete blood count and biochemical profile tests were measured before and after the immunization and experimental infection. The enzyme immunoassay (EIA) was used to detect any changes in the levels of specific IgG antibodies in sera from the mothers and infants; the agglutination test (AT) was used to measure titers of total anti-pertussis antibodies.Results. The intranasal immunization of P. hamadryas infants with the GamLVP vaccine triggered development of a specific humoral immune response mediated by IgG antibodies (pertussis toxin + filamentous hemagglutinin), increased titers of total agglutinating anti-pertussis antibodies, caused no local and systemic reactions, caused no changes in the complete blood count and biochemical profile. The experimental infection of the GamLVPimmunized P. hamadryas infants did not cause any changes in the laboratory blood test values and any clinical manifestations typical of the pertussis infection. |
| first_indexed | 2024-04-13T02:42:32Z |
| format | Article |
| id | doaj.art-d090f35323d34678864b5e82237fdb39 |
| institution | Directory Open Access Journal |
| issn | 0372-9311 2686-7613 |
| language | Russian |
| last_indexed | 2024-04-13T02:42:32Z |
| publishDate | 2022-05-01 |
| publisher | Central Research Institute for Epidemiology |
| record_format | Article |
| series | Журнал микробиологии, эпидемиологии и иммунобиологии |
| spelling | doaj.art-d090f35323d34678864b5e82237fdb392022-12-22T03:06:10ZrusCentral Research Institute for EpidemiologyЖурнал микробиологии, эпидемиологии и иммунобиологии0372-93112686-76132022-05-0199220321410.36233/0372-9311-190804Safety and immunogenicity of live intranasal pertussis vaccine GamLVP in the experimental infant hamadryas baboon modelA. A. Djidaryan0A. Z. Matua1A. Yu. Medkova2E. G. Semin3L. N. Sinyashina4I. N. Dyakov5I. N. Chernyshova6D. T. Kubrava7A. A. Amichba8I. G. Kondzariya9Z. Ya. Mikvabiya10G. I. Karataev11Research Institute of Experimental Pathology and Therapy of the Academy of Sciences of AbkhaziaResearch Institute of Experimental Pathology and Therapy of the Academy of Sciences of AbkhaziaNational Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. GamaleyaNational Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. GamaleyaNational Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. GamaleyaNational Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya; I. Mechnikov Research Institute for Vaccines and SeraNational Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya; I. Mechnikov Research Institute for Vaccines and SeraResearch Institute of Experimental Pathology and Therapy of the Academy of Sciences of AbkhaziaResearch Institute of Experimental Pathology and Therapy of the Academy of Sciences of AbkhaziaResearch Institute of Experimental Pathology and Therapy of the Academy of Sciences of AbkhaziaResearch Institute of Experimental Pathology and Therapy of the Academy of Sciences of AbkhaziaNational Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. GamaleyaIntroduction. The Gamaleya National Center of Epidemiology and Microbiology has developed a live intranasal pertussis vaccine, GamLVP, for protection against whooping cough. It is indicated for vaccination of infants and revaccination of adults of all age groups. Preclinical studies on suckling mice or rats and adult monkeys as well as clinical trials involving adult volunteers demonstrated safety and efficacy of the GamLVP vaccine. The expansion of the GamLVP vaccine to be used for vaccination of infants requires additional preclinical studies to assess its safety and immunogenicity in the most suitable experimental model of infant hamadryas baboons (Papio hamadryas).The aim of the study was to assess safety and immunogenicity of the GamLVP vaccine administered intranasally for a single dose, two-dose, and three-dose immunization of P. hamadryas infants.Materials and methods. The study was performed in three 1–2-month-old P. hamadryas infants kept, together with their mothers, in a separate cage. The results of the complete blood count and biochemical profile tests were measured before and after the immunization and experimental infection. The enzyme immunoassay (EIA) was used to detect any changes in the levels of specific IgG antibodies in sera from the mothers and infants; the agglutination test (AT) was used to measure titers of total anti-pertussis antibodies.Results. The intranasal immunization of P. hamadryas infants with the GamLVP vaccine triggered development of a specific humoral immune response mediated by IgG antibodies (pertussis toxin + filamentous hemagglutinin), increased titers of total agglutinating anti-pertussis antibodies, caused no local and systemic reactions, caused no changes in the complete blood count and biochemical profile. The experimental infection of the GamLVPimmunized P. hamadryas infants did not cause any changes in the laboratory blood test values and any clinical manifestations typical of the pertussis infection.https://microbiol.elpub.ru/jour/article/view/1218pertussislive pertussis vaccineintranasal administrationhamadryas baboonspapio hamadryasexperimental modelimmunogenicitysafety |
| spellingShingle | A. A. Djidaryan A. Z. Matua A. Yu. Medkova E. G. Semin L. N. Sinyashina I. N. Dyakov I. N. Chernyshova D. T. Kubrava A. A. Amichba I. G. Kondzariya Z. Ya. Mikvabiya G. I. Karataev Safety and immunogenicity of live intranasal pertussis vaccine GamLVP in the experimental infant hamadryas baboon model Журнал микробиологии, эпидемиологии и иммунобиологии pertussis live pertussis vaccine intranasal administration hamadryas baboons papio hamadryas experimental model immunogenicity safety |
| title | Safety and immunogenicity of live intranasal pertussis vaccine GamLVP in the experimental infant hamadryas baboon model |
| title_full | Safety and immunogenicity of live intranasal pertussis vaccine GamLVP in the experimental infant hamadryas baboon model |
| title_fullStr | Safety and immunogenicity of live intranasal pertussis vaccine GamLVP in the experimental infant hamadryas baboon model |
| title_full_unstemmed | Safety and immunogenicity of live intranasal pertussis vaccine GamLVP in the experimental infant hamadryas baboon model |
| title_short | Safety and immunogenicity of live intranasal pertussis vaccine GamLVP in the experimental infant hamadryas baboon model |
| title_sort | safety and immunogenicity of live intranasal pertussis vaccine gamlvp in the experimental infant hamadryas baboon model |
| topic | pertussis live pertussis vaccine intranasal administration hamadryas baboons papio hamadryas experimental model immunogenicity safety |
| url | https://microbiol.elpub.ru/jour/article/view/1218 |
| work_keys_str_mv | AT aadjidaryan safetyandimmunogenicityofliveintranasalpertussisvaccinegamlvpintheexperimentalinfanthamadryasbaboonmodel AT azmatua safetyandimmunogenicityofliveintranasalpertussisvaccinegamlvpintheexperimentalinfanthamadryasbaboonmodel AT ayumedkova safetyandimmunogenicityofliveintranasalpertussisvaccinegamlvpintheexperimentalinfanthamadryasbaboonmodel AT egsemin safetyandimmunogenicityofliveintranasalpertussisvaccinegamlvpintheexperimentalinfanthamadryasbaboonmodel AT lnsinyashina safetyandimmunogenicityofliveintranasalpertussisvaccinegamlvpintheexperimentalinfanthamadryasbaboonmodel AT indyakov safetyandimmunogenicityofliveintranasalpertussisvaccinegamlvpintheexperimentalinfanthamadryasbaboonmodel AT inchernyshova safetyandimmunogenicityofliveintranasalpertussisvaccinegamlvpintheexperimentalinfanthamadryasbaboonmodel AT dtkubrava safetyandimmunogenicityofliveintranasalpertussisvaccinegamlvpintheexperimentalinfanthamadryasbaboonmodel AT aaamichba safetyandimmunogenicityofliveintranasalpertussisvaccinegamlvpintheexperimentalinfanthamadryasbaboonmodel AT igkondzariya safetyandimmunogenicityofliveintranasalpertussisvaccinegamlvpintheexperimentalinfanthamadryasbaboonmodel AT zyamikvabiya safetyandimmunogenicityofliveintranasalpertussisvaccinegamlvpintheexperimentalinfanthamadryasbaboonmodel AT gikarataev safetyandimmunogenicityofliveintranasalpertussisvaccinegamlvpintheexperimentalinfanthamadryasbaboonmodel |